Beneficial Effects of the mTOR Inhibitor Everolimus in Patients with Advanced Medullary Thyroid Carcinoma: Subgroup Results of a Phase II Trial

Beneficial Effects of the mTOR Inhibitor Everolimus in Patients with Advanced Medullary Thyroid Carcinoma: Subgroup Results of a Phase II Trial

Objective. Until recently, advanced medullary thyroid cancer (MTC) had few treatment options except surgery. The mTOR inhibitor everolimus has shown encouraging results in neuroendocrine tumors. As part of a prospective phase II study, we analyzed the safety and efficacy of everolimus in advanced MT...

Ausführliche Beschreibung

Bibliographische Detailangaben
Hauptverfasser: T. C. Schneider, D. de Wit, T. P. Links, N. P. van Erp, J. J. M. van der Hoeven, H. Gelderblom, T. van Wezel, R. van Eijk, H. Morreau, H. J. Guchelaar, E. Kapiteijn
Format: Artikel
Sprache:English
Veröffentlicht: Hindawi Limited 2015-01-01
Schriftenreihe:International Journal of Endocrinology
Online Zugang:http://dx.doi.org/10.1155/2015/348124

Online

http://dx.doi.org/10.1155/2015/348124

Ähnliche Einträge